Gene therapy approaches for obesity-induced adipose neuropathy: Device-targeted AAV-mediated neurotrophic factor delivery to adipocytes in subcutaneous adipose
Molecular Therapy · 2024
DOI: 10.1016/j.ymthe.2024.02.035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2024. Verfasst von Magdalena Blaszkiewicz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, The Ohio State University, Columbus, OH 43210, USA. Hauptthemen laut MEDLINE: Dependovirus, Obesity, Genetic Therapy, Adipocytes. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIDDK NIH HHS, NIDDK.
Abstract (Originalsprache)
Maintaining functional adipose innervation is critical for metabolic health. We found that subcutaneous white adipose tissue (scWAT) undergoes peripheral neuropathy (PN) with obesity, diabetes, and aging (reduced small-fiber innervation and nerve/synaptic/growth-cone/vesicle markers, altered nerve activity). Unlike with nerve injuries, peripheral nerves do not regenerate with PN, and therefore new therapies are needed for treatment of this condition affecting 20-30 million Americans. Here, we validated a gene therapy approach using an adipocyte-tropic adeno-associated virus (AAV; serotype Rec2) to deliver neurotrophic factors (brain-derived neurotrophic factor [BDNF] and nerve growth factor [NGF]) directly to scWAT to improve tissue-specific PN as a proof-of-concept approach. AAVRec2-BDNF intra-adipose delivery improved tissue innervation in obese/diabetic mice with PN, but after longer periods of dietary obesity there was reduced efficacy, revealing a key time window for therapies. AAVRec2-NGF also increased scWAT innervation in obese mice and was more effective than BDNF, likely because Rec2 targeted adipocytes, the tissue's endogenous NGF source. AAVRec2-NGF also worked well even after 25 weeks of dietary obesity, unlike BDNF, which likely needs a vector that targets its physiological cellular source (stromal vascular fraction cells). Given the differing effects of AAVs carrying NGF versus BDNF, a combined therapy may be ideal for PN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurological Surgery, The Ohio State University, Columbus, OH 43210, USA.
- Department of Cancer Biology and Genetics, The Ohio State University, Columbus, OH 43210, USA.
- College of Engineering, University of Maine, Orono, ME 04469, USA.
- Department of Neurological Surgery, The Ohio State University, Columbus, OH 43210, USA; College of Engineering, University of Maine, Orono, ME 04469, USA. Electronic address: kristy.townsend@osumc.edu.
Förderung
- NCI NIH HHS
- NIDDK NIH HHS
- NIDDK
Zitieren
APA
Blaszkiewicz, M., Tao, T., Mensah-Arhin, K., Willows, J. W., Bates, R., Huang, W., Cao, L., Smith, R. L., & Townsend, K. L. (2024). Gene therapy approaches for obesity-induced adipose neuropathy: Device-targeted AAV-mediated neurotrophic factor delivery to adipocytes in subcutaneous adipose. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2024.02.035
Vancouver
Blaszkiewicz M, Tao T, Mensah-Arhin K, Willows JW, Bates R, Huang W, et al. Gene therapy approaches for obesity-induced adipose neuropathy: Device-targeted AAV-mediated neurotrophic factor delivery to adipocytes in subcutaneous adipose. Molecular Therapy. 2024. doi:10.1016/j.ymthe.2024.02.035
BibTeX
@article{Blaszkiewicz2024,
author = {Blaszkiewicz, Magdalena and Tao, Tianyi and Mensah-Arhin, Kofi and Willows, Jake W and Bates, Rhiannon and Huang, Wei and Cao, Lei and Smith, Rosemary L and Townsend, Kristy L},
title = {Gene therapy approaches for obesity-induced adipose neuropathy: Device-targeted AAV-mediated neurotrophic factor delivery to adipocytes in subcutaneous adipose},
journal = {Molecular Therapy},
year = {2024},
doi = {10.1016/j.ymthe.2024.02.035}
}
EUVIMED